Takeda

News

NICE turns down Takeda colorectal cancer drug

Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the grounds that it is not cost-effective.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Shifting the paradigm in pharma marketing with content trans...

Content transformation is changing pharmaceutical marketing. Join us to learn new strategies and approaches for this new world of patient centricity.

News

Epilepsy fail hands late-stage pipeline blow to Takeda

Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.

R&D

3rd to 7th June – This week in clinical trials

In this instalment of our clinical trials round-ups, we look at life sciences research and development announced during the week of 3rd to 7th June, from early-stage onwards.

News

Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot

Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy.

News

Iclusig gets FDA nod as frontline therapy for rare leukaemia

Takeda’s Iclusig has become the first targeted therapy approved by the FDA for use alongside chemotherapy as a first-line therapy for a rare form of acute lymphoblastic le

NICE turns down Takeda colorectal cancer drug

Shifting the paradigm in pharma marketing with content trans...

Epilepsy fail hands late-stage pipeline blow to Takeda

3rd to 7th June – This week in clinical trials

Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot

Iclusig gets FDA nod as frontline therapy for rare leukaemia

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Takeda

Editor's Picks